295 related articles for article (PubMed ID: 25112720)
1. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
[TBL] [Abstract][Full Text] [Related]
2. Extensive undertreatment of osteoporosis in older Swedish women.
Lorentzon M; Nilsson AG; Johansson H; Kanis JA; Mellström D; Sundh D
Osteoporos Int; 2019 Jun; 30(6):1297-1305. PubMed ID: 30805678
[TBL] [Abstract][Full Text] [Related]
3. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
[TBL] [Abstract][Full Text] [Related]
4. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
6. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
7. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
8. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
9. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
10. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
11. Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study.
Fraser LA; Ioannidis G; Adachi JD; Pickard L; Kaiser SM; Prior J; Brown JP; Hanley DA; Olszynski WP; Anastassiades T; Jamal S; Josse R; Goltzman D; Papaioannou A;
Osteoporos Int; 2011 Mar; 22(3):789-96. PubMed ID: 20683706
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
13. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces.
Crilly RG; Kloseck M; Chesworth B; Mequanint S; Sadowski E; Gilliland J
Osteoporos Int; 2014 Jan; 25(1):205-10. PubMed ID: 23907572
[TBL] [Abstract][Full Text] [Related]
15. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
[TBL] [Abstract][Full Text] [Related]
16. A survey of outcomes and management of patients post fragility fractures in China.
Wang O; Hu Y; Gong S; Xue Q; Deng Z; Wang L; Liu H; Tang H; Guo X; Chen J; Jia X; Xu Y; Lan L; Lei C; Dong H; Yuan G; Fu Q; Wei Y; Xia W; Xu L
Osteoporos Int; 2015 Nov; 26(11):2631-40. PubMed ID: 25966892
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU study.
Roux C; Cooper C; Díez-Pérez A; Martinez L; Ortolani S; Gitlin M; Möller G; Shepherd S; Freemantle N
Osteoporos Int; 2011 Apr; 22(4):1227-36. PubMed ID: 20628731
[TBL] [Abstract][Full Text] [Related]
18. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
[TBL] [Abstract][Full Text] [Related]
19. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
20. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
